Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients

Arthritis Care and Research

Volumn 64, Issue 12, 2012, Pages 1811-1818

  Jawaheer, Damini ^a   Messing, Susan ^b   Reed, George ^c   Ranganath, Veena K ^d   Kremer, Joel M ^e   Louie, James S ^d   Khanna, Dinesh ^f   Greenberg, Jeffrey D ^g   Furst, Daniel E ^d  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; MINOCYCLINE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX DIFFERENCE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84870487578     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21762     Document Type: Article

References (27)

1. Van Vollenhoven RF,. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-41.
2. Lipsky PE,. Are new agents needed to treat RA? [editorial]. Nat Rev Rheumatol 2009; 5: 521-2.
3. Anderson JJ, Wells G, Verhoeven AC, Felson DT,. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22-9.
4. Kvien TK, Uhlig T, Odegard S, Heiberg MS,. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006; 1069: 212-22.
5. Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE,. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 2010; 37: 2475-85.
6. Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011; 70: 469-75.
7. Hyrich KL, Watson KD, Silman AJ, Symmons DP,. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
8. Forslind K, Hafstrom I, Ahlmen M, Svensson B,. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 46-52.
9. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study. J Rheumatol 2007; 34: 1670-3.
10. Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al, for the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928-39.
11. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008; 59: 32-41.
12. Makinen H, Hannonen P, Sokka T,. Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis? Ann Rheum Dis 2008; 67: 1052-3.
13. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Luukkainen RK, et al, for the Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008; 58: 2642-51.
14. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al, for the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
15. Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG, et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol 2007; 25: 231-8.
16. Kremer JM,. The CORRONA database. Autoimmun Rev 2006; 5: 46-54.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
19. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
20. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl: S100-8.
21. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther 2009; 11: R7.
22. Jawaheer D, Olsen J, Hetland ML,. Sex differences in response to anti-TNF therapy in early and established rheumatoid arthritis: results from the DANBIO Registry. J Rheumatol 2012; 39: 46-53.
23. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011; 63: 856-64.
24. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A,. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 401-9.
25. Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC,. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (Oxford) 2009; 48: 1152-4.
26. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C,. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010; 62: 1128-43.
27. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS,. Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-9.